UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
- Once issued, this patent provides U.S. intellectual property coverage of UroGen's RTGel technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041
- 该专利一经颁发，将为UroGen的采用美达克冻干丝裂霉素配方的 rtGel 技术提供美国知识产权保障，涵盖截至 2041 年 12 月的 UGN-103 和 UGN-104 开发项目
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/535,108 entitled "Material and Method for Treating Cancer."
致力于开发和商业化治疗尿路上皮癌和特种癌症的创新解决方案的生物技术公司UroGen Pharma Ltd.（纳斯达克股票代码：URGN）今天宣布，它已收到美国专利商标局（USPTO）发出的题为 “治疗癌症的材料和方法” 的第18/535,108号专利申请许可通知。
The allowed claims relate to the combination of UroGen's RTGel technology with medac's licensed proprietary lyophilized mitomycin formulation and cover the use of UroGen's UGN-103 and UGN-104 development programs in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and low-grade upper tract urothelial cancer (LG-UTUC), respectively. The U.S. patent, once issued, will have an expiration date in December 2041.
允许的索赔涉及将UroGen的rtGel技术与medac许可的专有冻干丝裂霉素配方相结合，涵盖了UroGen的 UGN-103 和 UGN-104 开发计划分别用于治疗低度中等风险非肌肉浸润性膀胱癌（LG-IR-NMIBC）和低度上路尿路上皮癌（LG-UTUC）。美国专利一旦颁发，将在 2041 年 12 月到期。